On 20 May, China-headquartered Sirius Therapeutics and Swiss-based CRISPR Therapeutics announced a strategic partnership to co-develop and commercialise SRSD107, a next-gen long-acting siRNA therapy targeting Factor XI (FXI) for thrombotic diseases. Under the agreement, Sirius will receive USD 95 million upfront and over USD 800 million in potential milestone payments, with costs and profits shared equally. CRISPR gains US commercialisation rights, while Jingyin retains Greater China rights. SRSD107, designed to selectively inhibit FXI with reduced bleeding risk, has completed two Phase I trials and is advancing into Phase II studies for venous thromboembolism (VTE) prevention in knee replacement patients. The therapy holds potential for atrial fibrillation, cancer-associated thrombosis and other indications.